<DOC>
	<DOC>NCT02953847</DOC>
	<brief_summary>3-way cross-over single dose design evaluating bioavailability of 2 rifampicin-containing FDCs vs a single drug comparator in healthy volunteers</brief_summary>
	<brief_title>The Bioavailability of Rifampicin in (FDCs) Widely Used in South Africa to Treat Drug-susceptible (TB)</brief_title>
	<detailed_description>In this study the 4- and 2-drug FDCs (for intensive and continuation phases respectively) widely used within the South African treatment program will be evaluated in a comparative bioavailability study against a single drug rifampicin product registered by the South African Medicines Control Council. A three-way, single dose, cross-over study will be conducted in 24 healthy volunteers</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<criteria>Inclusion You need to be between the ages of 1855 years Have a Body mass index (BMI) of 1930 kg/m2 Weigh 45 kg or more Be a nonsmoker Be found to be in normal health on history and examination To have normal blood and urine test results If you are a woman of childbearing age, you need to be prepared to not have sexual intercourse, or use a safe form of contraception, until the end of the study Exclusion You are unable to fully understand and comply with the study procedures, requirements and time commitments. Are currently enrolled in any other study evaluating drugs, biologics or devices You have TB, or have had TB before You abuse or have abused drugs or alcohol You have, or have had, drug allergy, severe asthma, or active or recurrent allergic disease You are pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>